Answer
The product information reports no clinically important change in remimazolam pharmacokinetics across the studied range of renal impairment, although the clinical team must assess the whole patient.
Sources for this answer
- Byfavo 20mg powder for solution for injection — Current selected SmPCemc · Summary of Product Characteristics
- Byfavo 50 mg powder for concentrate for solution for injection/infusion — Current selected SmPCemc · Summary of Product Characteristics